论文部分内容阅读
目的研究分析乙型传染性肝炎疾病有效的治疗预后方法。方法选取我院收治的50例乙型传染性肝炎患者,分为两组,观察者及对照组,每组各25例,对照组采取给予干扰素α-2b治疗,观察组则在对照组的基础上联用恩替卡韦治疗,观察两组的治疗预后情况。结果观察组的总有效率为24(96%),对照组患者的治疗总有效率为19(76%),观察组的治疗总有效率明显高于对照组,且无严重的药物不良反应发生,差异具有统计学意义(P<0.05)。结论干扰素α-2b联合恩替卡韦对传染性肝炎患者的治疗及预后具有显著疗效,能够有效的帮助患者改善症状,提高生活质量,值得进一步用于临床应用及推广。
Objective To study and analyze the effective treatment prognosis of hepatitis B disease. Methods Fifty cases of hepatitis B patients admitted to our hospital were divided into two groups: observation group and control group, with 25 cases in each group. The control group was treated with interferon α-2b, and the observation group was in control group Based on the combination of entecavir treatment, the two groups observed the prognosis of treatment. Results The total effective rate was 24 (96%) in the observation group and 19 (76%) in the control group. The total effective rate in the observation group was significantly higher than that in the control group, and no serious adverse drug reaction occurred , The difference was statistically significant (P <0.05). Conclusion Interferon α-2b combined with entecavir has a significant effect on the treatment and prognosis of patients with infectious hepatitis, which can effectively help patients to improve their symptoms and improve their quality of life. They are worth further clinical application and promotion.